A recent study confirms that the 100-year-old BCG vaccine does not protect against COVID-19, challenging early assumptions ...

Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...

U.S. Urology Partners is one of the first providers to offer patients ImmunityBio’s recombinant Bacillus Calmette-Guérin (rBCG) The FDA recently authorized ImmunityBio’s EAP for rBCG to address U.S.

Working toward more effective tuberculosis (TB) vaccines, researchers at Weill Cornell Medicine have developed two strains of mycobacteria with "kill switches" that can be triggered to stop the ...

A live-attenuated tuberculosis (TB) vaccine candidate in development at Texas Biomedical Research Institute (Texas Biomed) ...

According to the company, the new, 225,000-square-foot expansion is a "crucial component" of a more than $12 billion infusion ...

The only licensed vaccine on the market—the Bacille Calmette-Guerin (BCG) vaccine—was invented more than 100 years ago and ...

Michigan has the only persisting bovine tuberculosis outbreak in wild deer anywhere in the U.S. — and it occasionally spills ...

IAVI and Biofabri are collaborating on the trial, which will recruit around 4,300 patients with latent TB infections across four countries.

Nadofaragene firadenovec intravesical gene therapy continues to show promise in treating BCG-unresponsive NMIBC bladder cancer.

At its sprawling complex in Durham, N.C., Merck has opened a new $1 billion, 225,000-square-foot manufacturing plant slated ...